fondaparinux has been researched along with Purpura--Thrombocytopenic--Idiopathic* in 2 studies
1 review(s) available for fondaparinux and Purpura--Thrombocytopenic--Idiopathic
| Article | Year |
|---|---|
[Heparin-induced thrombocytopenia: a brief update in an Italian perspective].
Type-2 heparin-induced thrombocytopenia (HIT) is a not infrequent complication of treatment with heparins which can lead to fatal outcomes if not recognized and timely treated. Over the last years new epidemiological knowledge, new diagnostic approaches and new therapeutic options have become available. In the present review such novelties will be briefly discussed in the frame of Italian Health System. In Italy only one drug is approved for use in HIT patients differently from other countries. Alternative possible therapeutic options will be discussed based on the scarce available evidence. Topics: Fondaparinux; Heparin; Hirudins; Humans; Italy; Platelet Activation; Platelet Factor 4; Polysaccharides; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Thromboembolism | 2007 |
1 other study(ies) available for fondaparinux and Purpura--Thrombocytopenic--Idiopathic
| Article | Year |
|---|---|
Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy.
Topics: Antibody Specificity; Anticoagulants; Autoantibodies; Betacoronavirus; Coronavirus Infections; COVID-19; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Pandemics; Platelet Count; Platelet Factor 4; Pneumonia, Viral; Purpura, Thrombocytopenic, Idiopathic; SARS-CoV-2; Thrombophilia | 2020 |